# Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diabetes In Korea

> **NCT00328965** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline**

## Conditions studied

- Diabetes Mellitus, Type 2
- Essential Hypertension

## Interventions

- **DRUG:** Lacidipine

## Key facts

- **NCT ID:** NCT00328965
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2006-05
- **Final completion:** 2006-05
- **Target enrollment:** — (—)
- **Last updated:** 2010-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00328965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00328965, "Lacidipine In Mild To Moderate Essential Hypertension Patients With Type 2 Diabetes In Korea". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00328965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*